PCNA and neoplasm: ApcMin/+/Faslpr mice had significantly more PCNA+ cells per tumor area than ApcMin/+ mice at most time points (p = 0.0014 at 8 weeks, p = 0.0038 at 16 weeks, p<0.0001 at 20 weeks and 30 weeks, n = 24–205 tumors for ApcMin/+/Faslpr and 18–58 tumors for ApcMin/+ in 4–5 mice per genotype) (Fig. 3).